Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
Status:
COMPLETED
Trial end date:
2025-08-14
Target enrollment:
Participant gender:
Summary
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer